FDA ad watch­dog sends first rep­ri­mand of 2023 to Xeris over ‘mis­lead­ing’ drug claims

It’s been one year since the FDA de­liv­ered a rep­ri­mand over phar­ma pro­mo­tions, end­ing the drought last week with an un­ti­tled let­ter to Xeris Phar­ma­ceu­ti­cals …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER